Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Guynes

Interventional Cardiology Jackson, MS Medical Doctor

NPI 1770526568 CMS profile 353010

970 Lakeland Dr, Suite 61, Jackson, MS 39216

Open in the dashboard

General payments

$26,220

684 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$66,483 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Richard Guynes of Jackson, MS is reported in the CMS Open Payments database as having received $26,220 across 684 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $66,483 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,171 113
2024 General $2,483 101
2023 General $2,036 90
2022 General $2,442 103
2021 General $1,978 78
2020 General $2,264 71
2019 General $11,846 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Guynes
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Richard Guynes were reported at $3,171. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Richard Guynes Interventional Cardiology median Middle half National median
2019 $11,846 $1,097 $329–$3,048 $163
2020 $2,264 $473 $161–$1,480 $114
2021 $1,978 $677 $233–$1,827 $132
2022 $2,442 $978 $333–$2,724 $149
2023 $2,036 $1,136 $382–$2,986 $160
2024 $2,483 $1,181 $395–$3,326 $164
2025 $3,171 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $5,905 160 payments
  2. Medtronic Vascular, Inc. $4,458 16 payments
  3. Edwards Lifesciences Corporation $3,936 12 payments
  4. Novartis Pharmaceuticals Corporation $2,235 151 payments
  5. Boston Scientific Corporation $1,880 43 payments
  6. AstraZeneca Pharmaceuticals LP $1,314 30 payments
  7. Merck Sharp & Dohme Corporation $812 37 payments
  8. Philips Electronics North America Corporation $765 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $574 23 payments
  10. Amgen Inc. $570 32 payments
  11. Other $3,772 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,451 670 payments
  2. Travel and Lodging $6,269 13 payments
  3. Honoraria $2,500 1 payment
Products named General payments · program years 2019–2025
  1. Impella $5,326 145 payments
  2. Resolute $4,444 15 payments
  3. LEQVIO $1,034 72 payments
  4. ENTRESTO $989 63 payments
  5. VERQUVO $910 42 payments
  6. WATCHMAN Access System $878 30 payments
  7. FARXIGA $626 12 payments
  8. Repatha $570 32 payments
  9. IGT_D Peripheral $555 2 payments
  10. XARELTO $532 32 payments
  11. Other $6,805 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

6,731

Median for Cardiology: 2,533

Drug cost

$1,183,716

Median for Cardiology: $485,213

Branded share of claims

33.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 706 $559,528
Xarelto Rivaroxaban Brand 278 $231,543
Entresto Sacubitril/Valsartan Brand 223 $176,301
Farxiga Dapagliflozin Propanediol Brand 70 $63,454
Brilinta Ticagrelor Brand 83 $38,740
Jardiance Empagliflozin Brand 41 $35,132
Repatha Sureclick Evolocumab Brand 36 $22,640
Metoprolol Succinate Generic 684 $7,699
Valsartan Generic 231 $4,135
Rosuvastatin Calcium Generic 586 $3,790

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$666,197

Of which drugs: $83,170

Medicare patients

2,129

Average age 75

Services billed

19,490

1,038 women, 1,091 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 52%
Diabetes 38%
Atrial fibrillation 31%
Chronic kidney disease 26%
Heart failure 24%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 15 8,520 $80,505
Injection, regadenoson, 0.1 mg J2785 Office 116 459 $2,241
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 44 4,225 $423

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$311 — 8,520
CAMZYOS
$186 — —
XARELTO
$111 278 —
VERQUVO
$98 — —
Wegovy
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

684 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record